NEW YORK, June 14, 2019 (GLOBE NEWSWIRE) -- Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Heron Therapeutics, Inc. (NASDAQ: HRTX) from October 31, 2018 through April 30, 2019, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Heron investors under the federal securities laws.

To join the Heron class action, go to http://pawarlawgroup.com/cases/heron-therapeutics-inc/ or call Vik Pawar, Esq. toll-free at 888-589-9804 or email info@pawarlawgroup.com for information on the class action.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Heron had failed to include adequate Chemistry, Manufacturing, and Controls and non-clinical information in its New Drug Application (“NDA”) with the U.S. Food and Drug Administration (“FDA”) for HTX-011; (2) the foregoing increased the likelihood that the FDA would not approve Heron’s NDA for HTX-011; and (3) as a result, Heron’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 5, 2019. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

No class has been certified.  Until a class is certified, you are not represented by counsel unless you hire one.  You may hire counsel of your choice.  You may also do nothing at this time and be an absent member of the class.  Your ability to share in any future recovery is not dependent upon being a lead plaintiff.

Pawar Law Group represents investors from around the world.
-------------------------------

Contact:
Vik Pawar, Esq.
Pawar Law Group
20 Vesey Street, Suite 1210
New York, NY 10007
Tel: (917) 261-2277
Fax: (212) 571-0938
info@pawarlawgroup.com